266 related articles for article (PubMed ID: 27104864)
61. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
62. [Mycosis fungoides and Sézary syndrome: diagnostic and prognostic relevance of cellular antigen expression].
Meissner K; Löning T; Rehpenning W
Hautarzt; 1991 Feb; 42(2):84-91. PubMed ID: 2037492
[TBL] [Abstract][Full Text] [Related]
63. Epidermal Langerhans cells and prognosis of patients with mycosis fungoides and Sezary syndrome.
Meissner K; Löning T; Rehpenning W
In Vivo; 1993; 7(3):277-80. PubMed ID: 8357970
[TBL] [Abstract][Full Text] [Related]
64. [Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].
Johno M; Ono T
Nihon Rinsho; 2000 Mar; 58(3):660-4. PubMed ID: 10741142
[TBL] [Abstract][Full Text] [Related]
65. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides.
Weinstock MA; Horm JW
Cancer; 1988 Oct; 62(8):1658-61. PubMed ID: 3167782
[TBL] [Abstract][Full Text] [Related]
66. Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome.
Allen PB; Goyal S; Niyogusaba T; O'Leary C; Ayers A; Tarabadkar ES; Khan MK; Lechowicz MJ
JAMA Dermatol; 2022 Nov; 158(11):1293-1299. PubMed ID: 36069854
[TBL] [Abstract][Full Text] [Related]
67. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
Quaglino P; Maule M; Prince HM; Porcu P; Horwitz S; Duvic M; Talpur R; Vermeer M; Bagot M; Guitart J; Papadavid E; Sanches JA; Hodak E; Sugaya M; Berti E; Ortiz-Romero P; Pimpinelli N; Servitje O; Pileri A; Zinzani PL; Estrach T; Knobler R; Stadler R; Fierro MT; Alberti Violetti S; Amitay-Laish I; Antoniou C; Astrua C; Chaganti S; Child F; Combalia A; Fabbro S; Fava P; Grandi V; Jonak C; Martinez-Escala E; Kheterpal M; Kim EJ; McCormack C; Miyagaki T; Miyashiro D; Morris S; Muniesa C; Nikolaou V; Ognibene G; Onida F; Osella-Abate S; Porkert S; Postigo-Llorente C; Ram-Wolff C; Ribero S; Rogers K; Sanlorenzo M; Stranzenbach R; Spaccarelli N; Stevens A; Zugna D; Rook AH; Geskin LJ; Willemze R; Whittaker S; Hoppe R; Scarisbrick J; Kim Y
Ann Oncol; 2017 Oct; 28(10):2517-2525. PubMed ID: 28961843
[TBL] [Abstract][Full Text] [Related]
68. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature.
Brown DN; Wieser I; Wang C; Dabaja BS; Duvic M
J Am Acad Dermatol; 2015 Dec; 73(6):976-86. PubMed ID: 26476898
[TBL] [Abstract][Full Text] [Related]
69. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.
Elsayad K; Kriz J; Moustakis C; Scobioala S; Reinartz G; Haverkamp U; Willich N; Weishaupt C; Stadler R; Sunderkötter C; Eich HT
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1077-86. PubMed ID: 26581145
[TBL] [Abstract][Full Text] [Related]
70. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
71. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
[TBL] [Abstract][Full Text] [Related]
72. Prognostic Significance of CD30 in Transformed Mycosis Fungoides.
Travaglino A; Russo D; Varricchio S; Pignatiello S; Baldo A; Picardi M; Pane F; Mascolo M
Am J Clin Pathol; 2021 Aug; 156(3):350-355. PubMed ID: 33769436
[TBL] [Abstract][Full Text] [Related]
73. CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
Edinger JT; Clark BZ; Pucevich BE; Geskin LJ; Swerdlow SH
Am J Surg Pathol; 2009 Dec; 33(12):1860-8. PubMed ID: 19898220
[TBL] [Abstract][Full Text] [Related]
74. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.
van Doorn R; Van Haselen CW; van Voorst Vader PC; Geerts ML; Heule F; de Rie M; Steijlen PM; Dekker SK; van Vloten WA; Willemze R
Arch Dermatol; 2000 Apr; 136(4):504-10. PubMed ID: 10768649
[TBL] [Abstract][Full Text] [Related]
75. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
Mori T; Shiratori S; Suzumiya J; Kurokawa M; Shindo M; Naoyuki U; Katsuto T; Miyamoto T; Morishige S; Hirokawa M; Fukuda T; Atsuta Y; Suzuki R
Hematol Oncol; 2020 Aug; 38(3):266-271. PubMed ID: 32011008
[TBL] [Abstract][Full Text] [Related]
76. Primary cutaneous lymphoma in southern Brazil: a 12-year single-center experience.
Nudelmann LM; Bonamigo RR
Int J Dermatol; 2015 Dec; 54(12):e512-20. PubMed ID: 26496535
[TBL] [Abstract][Full Text] [Related]
77. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
78. Mycosis fungoides and sezary syndrome: an update.
Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
[TBL] [Abstract][Full Text] [Related]
79. Mycosis fungoides and the Sézary syndrome.
Foss F
Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
[TBL] [Abstract][Full Text] [Related]
80. Prognostic factors and risk stratification in early mycosis fungoides.
Vonderheid EC; Pavlov I; Delgado JC; Martins TB; Telang GH; Hess AD; Kadin ME
Leuk Lymphoma; 2014 Jan; 55(1):44-50. PubMed ID: 23547839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
